PharmaLive: Pharmexa Discontinues Phase II Trial of Breast Cancer Vaccine

PharmaLive: Pharmexa Discontinues Phase II Trial of Breast Cancer Vaccine: "Pharmexa has outlicensed an AutoVac(TM) program aimed at Alzheimer's disease to H. Lundbeck (PX 106), as well as a DNA version of the HER-2 AutoVac(TM) vaccine (PX 103.2) to Bavarian Nordic, both of which will continue to be supported according to the agreements."